I'm LongbridgeAI, I can summarize articles.Johnson & Johnson (JNJ) added 2.68% this week to close at $275.23, against a 0.09% move for the S&P 500—an outperformance of about 2.59 percentage points. The stock swung 5.95% from low to high. It opened Monday at $267.125 and slipped to $265.17, then climbed through the week to an intraday high of $281.07 on Wednesday before settling at $275.23 on Friday. Average daily volume of about 6.42m shares came in roughly 15% below the week’s median of 7.56m.
The Week
Johnson & Johnson (JNJ) added 2.68% this week to close at $275.23, against a 0.09% move for the S&P 500—an outperformance of about 2.59 percentage points. The stock swung 5.95% from low to high. It opened Monday at $267.125 and slipped to $265.17, then climbed through the week to an intraday high of $281.07 on Wednesday before settling at $275.23 on Friday. Average daily volume of about 6.42m shares came in roughly 15% below the week’s median of 7.56m.
Key Events
Three company-specific themes stood out. J&J scheduled an investor call to discuss third-quarter 2026 results, with the earnings report set for 13 October before the open. On Wednesday, the stock rose about 3% as the firm completed an expansion at its Suzhou plant and began production on its first domestic electrophysiology line. European support for Tecvayli continued to draw attention to the company’s pipeline. Separately, EVP Timothy Schmid sold 33,597 shares worth $9.23m around Friday.
Analyst Ratings
Of 24 institutions covering J&J, 11 rate it buy, 5 overweight, 6 hold, 1 no opinion and 1 sell. The consensus rating is buy, with a consensus target of $275.64, about 14.76% above the spot price. Target prices range from $190.00 to $320.00, and that wide spread points to real disagreement about the upside. Within the 205-stock pharmaceutical sector, J&J ranks fifth by analyst rating.
The Week Ahead
The macro calendar includes the NFIB small-business optimism index on Tuesday and a dense Thursday of US jobless claims and PPI prints. On the company side, attention will drift toward the 13 October pre-market Q3 report, with estimates at $2.07 EPS and roughly $25.2bn in revenue.
In Short
J&J’s shares moved higher with a broadly constructive analyst stance, though targets from $190 to $320 show the street is not aligned on the path forward. The latest session’s money flow skews retail: large-lot orders were net sellers while medium and small orders were net buyers. The next major catalyst is next month’s Q3 update, which should reset expectations across the company’s main product lines.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.